Welcome to our dedicated page for Baxter Intl news (Ticker: BAX), a resource for investors and traders seeking the latest updates and insights on Baxter Intl stock.
Baxter International Inc. (NYSE: BAX) is a global medtech company whose news flow reflects its focus on connected care technologies, medical devices and advanced injectable therapies. On this page, readers can follow company announcements that illustrate how Baxter’s products and partnerships intersect with hospital operations, nursing workflows and patient safety.
Recent Baxter news highlights the launch of the Dynamo Series smart stretcher, designed for emergency departments, perioperative environments and patient transport services. Baxter reports that the Dynamo Series is intended to reduce the need for patient transfers, support a range of procedures in-stretcher, and incorporate technologies such as SafeView+ visual cues, bed exit alarms and optional connectivity to EMRs and nurse call systems to help prevent patient falls and support care teams.
Other updates include a multi-year strategic partnership with MUSC Health focused on integrating connected care technologies at the bedside. Baxter and MUSC Health describe objectives such as standardizing and simplifying bedside technologies, reducing documentation time, streamlining communication, improving nurse satisfaction and retention, and using real-time insights and advanced monitoring to enhance quality and safety outcomes.
Baxter also issues news on its infusion therapy portfolio, such as real-world data presented with The University of Texas Medical Branch on the Spectrum IQ large volume infusion pumps. These analyses examine how smart pump integration with electronic medical records may affect patient safety alerts, infusion programming time and clinician workload.
In addition, investors can find announcements on capital allocation decisions, including tender offers for senior notes, new note issuances and dividend declarations, as well as philanthropic news from the Baxter Foundation, such as grants to support STEM education through the Baxter Center for Science Education. Bookmark this page to access Baxter’s latest product, partnership, financial and community impact news in one place.
Baxter, a global leader in medical technology, announced that it will present at the Goldman Sachs 45th Annual Global Healthcare Conference. This event is scheduled for June 12, 2024, at 8:40 a.m. Eastern Time. Baxter's CFO, Joel Grade, will represent the company, providing insights into its financial position and future directions. The presentation will be available via live webcast on Baxter's official website and can be replayed through December 9, 2024.
Baxter announced that its expanded hemodialysis (HDx) therapy, enabled by the Theranova dialyzer, has shown to reduce all-cause mortality by approximately 25% over four years compared to high-flux hemodialysis (HF HD). The findings come from a cohort study involving 1,092 dialysis patients in Colombia, presented at the ERA-EDTA Congress. Of these, 533 patients received HF HD, while 559 received HDx therapy. The study emphasized HDx therapy's efficiency in removing large-middle molecule uremic toxins, linked to inflammation and cardiovascular issues in dialysis patients. HDx therapy uses the MCO membrane for better filtration and is compatible with existing HD machines, simplifying its implementation in clinics. Over 14 million HDx treatments have been conducted worldwide.
Baxter International (NYSE:BAX), a leading medtech company, is set to present at the Jefferies 2024 Global Healthcare Conference on June 5, 2024.
The presentation will be led by Joel Grade, Baxter's CFO, at 9:30 a.m. Eastern Time.
The event will be webcast live and accessible via Baxter's website, with a replay available until December 2, 2024.
Baxter International announced the mission and logo for its proposed kidney care and acute therapies company, Vantive. The mission, "Extending Lives, Expanding Possibilities," will guide Vantive in developing solutions for acute and chronic kidney diseases. The new logo, featuring a "V" motif in plum color, symbolizes the company's commitment to innovative therapies, digital solutions, and advanced services.
Vantive will build upon Baxter's nearly 70-year legacy in kidney care, aiming to improve outcomes for over one million patients annually across more than 70 countries. The separation of Vantive from Baxter's Renal Care and Acute Therapies businesses is expected to occur in the second half of 2024, either through a private equity sale or a public spinoff.
Baxter International Inc. (NYSE:BAX) has received FDA approval for an expanded indication for Clinolipid (Lipid Injectable Emulsion) for pediatric patients, including preterm and term neonates. Clinolipid provides essential fatty acids and calories for parenteral nutrition when oral or enteral nutrition is not possible. The approval highlights Baxter's commitment to meeting the nutritional needs of patients of all ages.
Baxter International Inc. (NYSE:BAX) will present at the Bank of America 2024 Health Care Conference with its chief financial officer, Joel Grade, scheduled to speak on May 15, 2024. The live webcast will be available for replay until August 14, 2024. Baxter is a global medtech leader offering a variety of healthcare products and solutions across the world.
Baxter International Inc. (NYSE:BAX) has declared a quarterly cash dividend of $0.29 per share of common stock, with an indicated annual dividend rate of $1.16 per share. The dividend will be payable on July 1, 2024, to stockholders of record as of May 31, 2024.
Baxter International Inc. reported first-quarter 2024 results with sales of $3.59 billion, up 2% on a reported basis and 3% on a constant currency basis, surpassing guidance. U.S. GAAP EPS was $0.07, adjusted EPS was $0.65. Full-year sales growth outlook is 2% (reported) and 2-3% (constant currency). Recent FDA clearance of Novum IQ large volume infusion pump and Dose IQ Safety Software. Baxter is focused on operational execution, innovation, and value creation for stakeholders.
Summary not available.
Summary not available.